ST. PAUL, Minn., Dec. 20, 2018 /PRNewswire/ -- Squarex, a clinical-stage pharmaceutical company developing a topical immunomodulator for the long-term prevention of recurrent cold sores, today announced that its Founder and President, Hugh McTavish, Ph.D., will present at Biotech Showcase 2019, held January 6-9, 2019, at the Hilton San Francisco Union Square.
Dr. McTavish will discuss Squarex's lead clinical asset, a topical formulation of squaric acid dibutyl ester designed to prevent recurrent cold sores caused by herpes labialis, which is currently in Phase 2 clinical development.
Details of Squarex's presentation are as follows:
Event: | Biotech Showcase 2019 | |
Date: | Tuesday, January 8, 2019 | |
Time: | 11 a.m. (Pacific Time) | |
Location: | Hilton San Francisco Union Square |
About Squarex
Squarex is a clinical-stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Viruses. Their Phase 1/2 placebo-controlled clinical trial showed the drug was safe and effective in preventing cold sore outbreaks, tripling the time to next cold sore outbreak from 40 days to more than 120. Pending approval, this would be the first and only drug on the market to prevent cold sore outbreaks in the more than 2% of the U.S. population with 6+ outbreaks per year.
Contacts:
Tiberend Strategic Advisors, Inc.
Jonathon Brzezinski, Ph.D. (Investors)
jbrzezinski@tiberend.com
(212) 375-2681
David Schemelia (Media)
dschemelia@tiberend.com
(212) 375-2686
SOURCE Squarex
